NCT03265002 (EFIGI) is a NA clinical trial of Inulin in Irritable Bowel Syndrome, sponsored by University of Nottingham.

Who is sponsoring NCT03265002?

NCT03265002 is sponsored by University of Nottingham.

What drugs are being tested in NCT03265002?

Interventions in NCT03265002: Placebo, Inulin, Psyllium, Inulin and psyllium.

What condition does NCT03265002 study?

NCT03265002 studies Irritable Bowel Syndrome.

Is NCT03265002 still recruiting?

NCT03265002 is currently completed. Last updated 25 March 2020.

Last reviewed 2020-03-25 · How we verify

NCT03265002: EFIGI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fibre and Gas in Irritable Bowel Syndrome

Completed NA Last updated 25 March 2020

What this trial tests

NA trial testing Placebo in Irritable Bowel Syndrome in 19 participants. Completed in 16 October 2019.

Timeline

8 March 2018

Primary endpoint
16 October 2019

16 October 2019

Quick facts

Lead sponsor	University of Nottingham
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	19
Start date	8 March 2018
Primary completion	16 October 2019
Estimated completion	16 October 2019
Sites	1 location across United Kingdom

Drugs / interventions tested

Placebo
Inulin — full drug profile →
Psyllium
Inulin and psyllium

Conditions studied

Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →

Sponsor

University of Nottingham

Who can join

Adults 16 to 65, any sex, with Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to investigate how dietary fibre combinations affects gut physiology, particularly colonic gas production. Comparisons will be made between a single fermentable fibre (inulin), a non-fermentable fibre (psyllium) and a combination of the two. The study will also explore differences in response between diarrhoea-predominant and constipation-predominant IBS (IBS-D and IBS-C) respectively. The participants will have a preliminary meeting to ensure they are eligible, then will attend the MRI department on 4 occasions separated by at least 1 week. They will ingest a drink with the fibre product mixed in, and will have 8 MRI scans (each lasting approximately 15 minutes).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Psyllium reduces inulin-induced colonic gas production in IBS: MRI and <i>in vitro</i> fermentation studies.
Gunn D, Abbas Z, Harris HC, Major G, et al · · 2022 · cited 33× · PMID 34353864 · DOI 10.1136/gutjnl-2021-324784

Verify or expand the search:

Other trials of Inulin

Trials testing the same drug.

NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
NCT07525180 — Comparing Prebiotic Fiber Supplements for Gut Health and Digestive Comfort · NA · not yet recruiting
NCT06372249 — A Clinical Trial of Soluble Fiber for Asthma · Phase 2 · recruiting
NCT06866262 — Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell · Phase 1, PHASE2 · recruiting
NCT06607523 — The Gut-Brain Axis During Neurorehabilitation; Prebiotic Treatment to Alter the Gut Microbiome and Neurologic Symptoms · NA · recruiting

Other recruiting trials for Irritable Bowel Syndrome

Currently open trials in the same condition.

NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting

Other University of Nottingham trials

Trials by the same sponsor.

NCT07518381 — Medication Understanding in MS · not yet recruiting
NCT07355556 — Technology Supported Improvement, Management and Prevention of Accidental Falls in Hospitals · not yet recruiting
NCT07506408 — Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Gene · NA · recruiting
NCT07237529 — What is the Feasibility of Narrative Exposure Therapy (NET) for People Experiencing Psychosis? · NA · not yet recruiting
NCT07237997 — Protein Supplementation During Dialysis (PROSED) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03265002 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nottingham
Last refreshed: 25 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03265002.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing